Lenalidomide and Paclitaxel in Prostate Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 31, 2009

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Prostate Cancer
Interventions
DRUG

Lenalidomide

Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.

DRUG

Paclitaxel

50 mg/m\^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER